In contrast, a variety of tumors including breast, colon, ovary, and prostate cancer express elevated FASN levels [17–23], since tumor cells become less sensitive to regulatory nutritional signals and prefer the de novo lipogenesis pathway. This evidence concerns the gene FASN and Familial prostate cancer.